ACTRN12610000871044已完成1 期
A Phase I study to assess the safety of three formulations of the dermal implant ELAPR in healthy subjects.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Good general health status
排除标准
- •Clinically significant abnormalities of haematology or
- •biochemistry testing
- •Bleeding diathesis, anticoagulant drugs,
- •thrombocytopenia or clinically significant prolonged
- •Chronic use of aspirin, other non-steroidal antiinflammatory
- •drugs or other anti-platelet agents
- •History of keloid formation
- •Systemic corticosteroids within last 12 weeks
- •Diabetes or metabolic disorders
- •Any serious medical condition which in the opinion of
- •the investigator would have a strong possibility of
- •requiring systemic corticosteroid medication
- •Pregnancy/lactation
- •A history of anaphylaxis or allergic reactions including
- •any known hypersensitivity to Hyaluronic acid or
研究者
相似试验
进行中（未招募）
1 期
A Three-part, Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Topical Doses of TCP-25 in Healthy Male and Female Volunteers with Epidermal Suction Blister Wounds and in Patients with Non-Healing Leg Ulcers and Patients with XYZTCP-25 gel targets both bacteria and inflammation, aspects common to many wounds and is being developed for a range of wound healing indications including prevention and treatment of infection and inflammation in XYZ and in other acute or non-healing wounds.EUCTR2021-004728-14-SEXinnate AB35
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat Severe Sickle Cell DiseaseSevere Sickle Cell Disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001320-19-BEVertex Pharmaceuticals Incorporated45
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat Severe Sickle Cell DiseaseSevere Sickle Cell Disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001320-19-DEVertex Pharmaceuticals Incorporated45
进行中（未招募）
不适用
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR MutationMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-000604-41-IEVertex Pharmaceuticals Incorporated1,000
进行中（未招募）
1 期
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR MutationMedDRA version: 18.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-000604-41-ATVertex Pharmaceuticals Incorporated1,000